Evofem Amends Adjuvant Notes: Full Repayment Due December 1, 2026
EVFM is trading near its 52-week low of $0.478 (99% below the low).
Summary
Evofem amended its Adjuvant convertible note agreement to make the notes payable in full by December 1, 2026, with no prepayment allowed before then — a near-term repayment obligation for a company that has already warned its cash cannot fund operations for 12 months.
Key Events · Financing and Capital Events · EVFM
-
Fifth Amendment Sets December 1, 2026 Maturity
On October 9, 2026, Evofem and the Adjuvant funds amended the October 14, 2020 Securities Purchase Agreement so the convertible notes are due in full on the earliest of December 1, 2026, a Change of Control consummation elected by Adjuvant, or acceleration under Section 8.
-
No Prepayment Before December 1, 2026
The notes may not be prepaid prior to December 1, 2026 without Adjuvant's prior written consent, so the company cannot retire the obligation early on its own terms.
-
Affirmative Covenant Deleted
Section 7.1(f) of the purchase agreement was deleted in its entirety and replaced with '[Reserved]', removing an affirmative covenant from the agreement.
-
Repayment Due Against Going-Concern Warning
The 10-Q filed August 14, 2026 reported a $16.5 million net loss for H1 2026 and stated cash is insufficient to fund operations for the next 12 months, raising substantial doubt about the company's ability to continue.
Analysis · EVFM · Life Sciences
A fifth amendment to the 2020 purchase agreement, signed with the Adjuvant funds, now fixes a hard repayment date of December 1, 2026 — roughly seven weeks from today — unless Adjuvant elects to accelerate on a change of control. The notes also cannot be prepaid before that date without Adjuvant's consent, and an affirmative covenant was deleted outright. This lands on top of the company's own 10-Q warning that cash is insufficient to fund operations for the next 12 months. A near-term, non-pre-payable maturity of this kind leaves Evofem with a narrow window to refinance, renegotiate again, or raise equity — and the removal of a covenant suggests the lender, not the company, is setting terms. The stock trades near its 52-week low, which limits how much a new equity raise could realistically bring in.
How filings like this one have moved
In the 30 days to Nov 2, 2026, 40.4% of the 1069 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.35%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, EVFM was trading at $0.01 on OTC in the Life Sciences sector, with a market capitalization of approximately $927.7K. The 52-week trading range was $0.48 to $0.48. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.